{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:27:35Z","timestamp":1792315655246,"version":"4.4.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"DOI":"10.7759\/cureus.74541","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T06:13:52Z","timestamp":1732688032000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Supratherapeutic Duloxetine Combined With Cognitive-Behavioral Therapy in Severe Treatment-Resistant Obsessive-Compulsive Disorder With Comorbid Depression: A Case Report"],"prefix":"10.7759","author":[{"given":"Syed Ali","family":"Bokhari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen T","family":"Alawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2006.05.002","article-title":"Depressive disorders in childhood and adolescence: an overview: epidemiology, clinical manifestation and risk factors","volume":"15","author":"Zalsman G","year":"2006","unstructured":"Zalsman G, Brent DA, Weersing VR. Depressive disorders in childhood and adolescence: an overview: epidemiology, clinical manifestation and risk factors. Child Adolesc Psychiatr Clin N Am. 2006, 15:827-41, vii. 10.1016\/j.chc.2006.05.002","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.8.4.527","article-title":"Duloxetine in the treatment of major psychiatric and neuropathic disorders","volume":"8","author":"M\u00fcller N","year":"2008","unstructured":"M\u00fcller N, Schennach R, Riedel M, M\u00f6ller HJ. Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Rev Neurother. 2008, 8:527-36. 10.1586\/14737175.8.4.527","journal-title":"Expert Rev Neurother"},{"key":"ref3","article-title":"SNRIs pharmacological alternatives for the treatment of obsessive compulsive disorder?","volume":"8","author":"Sansone RA","year":"2011","unstructured":"Sansone RA, Sansone LA. SNRIs pharmacological alternatives for the treatment of obsessive compulsive disorder?. Innov Clin Neurosci. 2011, 8:10-4.","journal-title":"Innov Clin Neurosci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107079865","article-title":"Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series","volume":"22","author":"Dell'osso B","year":"2008","unstructured":"Dell'osso B, Mundo E, Marazziti D, Altamura AC. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol. 2008, 22:210-3. 10.1177\/0269881107079865","journal-title":"J Psychopharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/15622970802465807","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision","volume":"9","author":"Bandelow B","year":"2008","unstructured":"Bandelow B, Zohar J, Hollander E, et al.. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008, 9:248-312. 10.1080\/15622970802465807","journal-title":"World J Biol Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31817f8cef","article-title":"High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission","volume":"32","author":"Yeh YW","year":"2009","unstructured":"Yeh YW, Chen CH, Kuo SC, Wang SC, Chen CK, Feng HM. High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission. Clin Neuropharmacol. 2009, 32:174-6. 10.1097\/WNF.0b013e31817f8cef","journal-title":"Clin Neuropharmacol"},{"key":"ref7","article-title":"Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report","volume":"9","author":"Safer DL","year":"2012","unstructured":"Safer DL, Arnow KD. Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report. Innov Clin Neurosci. 2012, 9:13-6.","journal-title":"Innov Clin Neurosci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster FP","year":"2001","unstructured":"Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al.. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001, 25:871-80. 10.1016\/S0893-133X(01)00298-6","journal-title":"Neuropsychopharmacology"},{"key":"ref9","article-title":"Essential Psychopharmacology: The Prescriber's Guide: Revised and Updated Edition","author":"Stahl SM","year":"2006","unstructured":"Stahl SM. Essential Psychopharmacology: The Prescriber's Guide: Revised and Updated Edition. Cambridge University Press, Cambridge, England; 2006."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.04.068","article-title":"Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: a meta-analysis","volume":"218","author":"Sugarman MA","year":"2017","unstructured":"Sugarman MA, Kirsch I, Huppert JD. Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: a meta-analysis. J Affect Disord. 2017, 218:217-26. 10.1016\/j.jad.2017.04.068","journal-title":"J Affect Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton M","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960, 23:56-62. 10.1136\/jnnp.23.1.56","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown obsessive compulsive scale. I. development, use, and reliability","volume":"46","author":"Goodman WK","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, et al.. The Yale-Brown obsessive compulsive scale. I. development, use, and reliability. Arch Gen Psychiatry. 1989, 46:1006-11. 10.1001\/archpsyc.1989.01810110048007","journal-title":"Arch Gen Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyu062","article-title":"Open-label study of duloxetine for the treatment of obsessive-compulsive disorder","volume":"18","author":"Dougherty DD","year":"2015","unstructured":"Dougherty DD, Corse AK, Chou T, et al.. Open-label study of duloxetine for the treatment of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2015, 18:pyu062. 10.1093\/ijnp\/pyu062","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000592","article-title":"Duloxetine augmentation in resistant obsessive-compulsive disorder: a double-blind controlled clinical trial","volume":"36","author":"Mowla A","year":"2016","unstructured":"Mowla A, Boostani S, Dastgheib SA. Duloxetine augmentation in resistant obsessive-compulsive disorder: a double-blind controlled clinical trial. J Clin Psychopharmacol. 2016, 36:720-3. 10.1097\/JCP.0000000000000592","journal-title":"J Clin Psychopharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/321363-efficacy-of-supratherapeutic-duloxetine-combined-with-cognitive-behavioral-therapy-in-severe-treatment-resistant-obsessive-compulsive-disorder-with-comorbid-depression-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T06:14:01Z","timestamp":1732688041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/321363-efficacy-of-supratherapeutic-duloxetine-combined-with-cognitive-behavioral-therapy-in-severe-treatment-resistant-obsessive-compulsive-disorder-with-comorbid-depression-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.74541","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,26]]}}}